Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S. Spector NL, et al. Among authors: koch km. J Clin Oncol. 2005 Apr 10;23(11):2502-12. doi: 10.1200/JCO.2005.12.157. Epub 2005 Jan 31. J Clin Oncol. 2005. PMID: 15684311 Clinical Trial.
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Burris HA 3rd, et al. Among authors: koch km. J Clin Oncol. 2005 Aug 10;23(23):5305-13. doi: 10.1200/JCO.2005.16.584. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955900 Clinical Trial.
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Burris HA 3rd, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, Wilding G. Burris HA 3rd, et al. Among authors: koch km. Clin Cancer Res. 2009 Nov 1;15(21):6702-8. doi: 10.1158/1078-0432.CCR-09-0369. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825948 Free PMC article. Clinical Trial.
Effect of lapatinib on oral digoxin absorption in patients.
Koch KM, Smith DA, Botbyl J, Arya N, Briley LP, Cartee L, White JH, Beyer J, Dar MM, Chung HC, Chu Q, Bang YJ. Koch KM, et al. Clin Pharmacol Drug Dev. 2015 Nov;4(6):449-53. doi: 10.1002/cpdd.189. Epub 2015 Jun 2. Clin Pharmacol Drug Dev. 2015. PMID: 27137717 Clinical Trial.
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
Devriese LA, Koch KM, Mergui-Roelvink M, Matthys GM, Ma WW, Robidoux A, Stephenson JJ, Chu QS, Orford KW, Cartee L, Botbyl J, Arya N, Schellens JH. Devriese LA, et al. Among authors: koch km. Invest New Drugs. 2014 Jun;32(3):481-8. doi: 10.1007/s10637-013-0055-4. Epub 2013 Dec 19. Invest New Drugs. 2014. PMID: 24346280 Clinical Trial.
404 results